Chongqing - A summit on developing clinical diagnosis and treatment technologies was held in Southwest China's Chongqing on May 27, drawing over 60 industry experts at home and abroad. 

Experts discussed new technologies in immunotherapy and clinical treatment challenges in infectious diseases, tumors, aging, etc. 

For example, Academician Chen Zhinan delivered a presentation on the topic of the status quo and the development of biotechnology drugs. Combining with his team's work, he provided insights into the industrial status, trends, and directions of antibody drugs worldwide. 

The summit also contributed to the cooperation between Chongqing International Institute for Immunology and Danaher (Shanghai) Management Co., Ltd. 

To develop China's immune biotherapy industry and create a new pathway for the immune-based economy, both parties will collaborate on establishing the human immune evaluation center, specialized immunology hospital, and others. 

The Chongqing International Immunology Research Institute is the first new high-end immunology research and development institution in China, generating cutting-edge knowledge in basic immunology, clinical immunology, and biotechnology.

Danaher Group, a Fortune 500 global innovator in science and technology, possesses advanced life sciences and medical diagnostics technologies. The company is committed to providing state-of-the-art life science technologies and tools to the pharmaceutical and health industries, accelerating solutions from technology development to commercial translation.

As a leading force in Chongqing's biopharmaceutical industry, Chongqing International Immunology Research Institute aims to build a leading original innovation hub in the western region for life sciences. 

Through solid collaboration among various stakeholders, the institute has made positive progress, leading the world to launch the human immune decoding program.

This program will unite with other academic organizations to decode the immune tissues, cells, molecules, and genes involved in human physiological, pathological, and disease processes. It aims to incubate new medical industry ventures and achieve self-reliance in technology and national industries.

In recent years, Chongqing has strongly developed biotechnology for clinical diagnosis. The Chongqing international biotech industrial park is another crucial industry carrier, which has 54 innovative drugs under research, with 23 entering the clinical stage and nine reaching Phase III trials. It has achieved national leadership in HPV vaccines, insulin, and antibody drugs.